n.a. (ONXX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Biotech M&A deals that haven't happened because of price argue against the risk of a bubble.

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Trade-Ideas LLC identified Onyx Pharmaceuticals (ONXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Washington and a number of stocks.

Grading the Twitterverse's 2013 Biotech Stock Picks

Grading the Twitterverse's 2013 Biotech Stock Picks

Some of your predictions were spot on, others not so much.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Onyx Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Amgen Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Onyx Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Amgen Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Onyx Pharmaceuticals (“Onyx”...

Cramer's 'Mad Money' Recap: More Selling to Come

Cramer's 'Mad Money' Recap: More Selling to Come

There's nothing to like about today's down market, especially when it doesn't reflect all the bad news, Cramer said.

Cramer's 'Mad Money' Recap: A Market Too Good to Ignore

Cramer's 'Mad Money' Recap: A Market Too Good to Ignore

It's hard to hate a market that's making so many new highs, Cramer said.

Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Winner

Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Winner

Onyx Pharmaceuticals was a winner within the drugs industry, rising $6.53 (5.6%) to $123.49 on heavy volume

Stocks Drop as U.S. Challenges Syria's Chemical Attack

Stocks Drop as U.S. Challenges Syria's Chemical Attack

The markets sell off after Secretary of State John Kerry says evidence is undeniable that Syria launched a chemical weapons attack.

Onyx Pharmaceuticals Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Merger With Amgen, Inc.

Onyx Pharmaceuticals Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Merger With Amgen, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the merger of Onyx Pharmaceuticals, Inc.

The Deal: Amgen Soars on $10.4B Onyx Deal

The Deal: Amgen Soars on $10.4B Onyx Deal

The buyer bolsters its pipeline of cancer treatments with target's myeloma drug.

Law Firm Brower Piven Announces Investigation Of Onyx Pharmaceuticals, Inc. Proposed Buyout

Law Firm Brower Piven Announces Investigation Of Onyx Pharmaceuticals, Inc. Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Onyx Pharmaceuticals, Inc.

Amgen Regains Biotech Growth Cred With $10B Onyx Acquisition

Amgen Regains Biotech Growth Cred With $10B Onyx Acquisition

Amgen will benefit from bolstered top-line growth, instead of relying on financial hocus-pocus to boost earnings.

Cramer on Mergers and Markets

Cramer on Mergers and Markets

Jim Cramer gives his take on trending Twitter topics including Amgen's purchase of Onyx and the fallout from Nasdaq's trading glitch.

Stock Futures Weak While Onyx Surges

Stock Futures Weak While Onyx Surges

Stock futures are little changed Monday as investors mull the question of when the Fed will begin curbing its stimulus measures.

Mergers Don't Lift Stocks

Mergers Don't Lift Stocks

Mergers from Amgen, Onyx and TMS International aren't enough to persuade stocks to move higher. Qihoo investors are happy with its earnings.

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Onyx Pharmaceuticals (ONXX) as a pre-market mover with heavy volume candidate

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures point to losses on Wall Street; Amgen agrees to buy Onyx for $10.4 billion; New York's attorney general sues Donald Trump; Muriel Siebert dies.

Amgen Buying Cancer Drug Maker Onyx for $10.4 Billion

Amgen Buying Cancer Drug Maker Onyx for $10.4 Billion

Amgen Inc. said Sunday it will acquire Onyx for $125 per share, and it expects to complete the deal at the beginning of the fourth quarter.

Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout

Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout

Onyx's decision to buy privately held Proteolix in October 2009 was a jackpot.

Amgen and Onyx Pharmaceuticals Reported to be Near Deal

Amgen and Onyx Pharmaceuticals Reported to be Near Deal

An announcement of a deal could be made as early as Monday, according to news reports.

A Time to Test Biotechs' Strength

A Time to Test Biotechs' Strength

The fundamentals are good and most of the companies are sound, but a string of soaring IPOs has some investors asking whether the run can last.

Stock Futures Get Lift From Overseas Data; Jobless Claims Rise

Stock Futures Get Lift From Overseas Data; Jobless Claims Rise

Stock futures are pointing to a higher open on Wall Street Thursday following encouraging economic data from China and Europe.

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures rise; China factory output improves; HP revenue declines; Yahoo! tops Google in Web traffic.